Equity Research Biotechnology

Should You Buy Can-Fite BioPharma Ltd. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Can-Fite BioPharma Ltd. (CANF) registers a weak Quality of Company score of 2.5/10. At the current price of $2.24, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.

The short answer: 0 of 0 CirclFi valuation models project upside for Can-Fite BioPharma Ltd. (CANF) at $2.24 — the models are evenly split, with a Quality Score of 2.5/10 and Value-Trap risk of 80/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 2.5/10 — Very Weak — significant concerns
  • Value Trap Risk: 80/100 — High danger — likely trap
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

2.5 /10

Very Weak — significant concerns

Value Trap Risk

80 /100
High danger

High danger — likely trap

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for Can-Fite BioPharma Ltd. (CANF) in 2026?

What Is the Bull Case vs the Bear Case for Can-Fite BioPharma Ltd. (CANF)?

Bull case versus bear case for Can-Fite BioPharma Ltd. (CANF) at $2.24, derived from 0 active CirclFi valuation models on 2026-09-15.
Bull case Bear case
No active model projects meaningful upside for CANF at $2.24. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for CANF. The Value Trap score of 80/100 still argues for some caution.

How Does CANF Compare to Its Biotechnology Peers?

GLMD Eocene Ltd.
2.5
TLSA Tiziana Life Science
2.5
SLGL Sol-Gel Technologies
2.5
EPRX Eupraxia Pharmaceuti
2.4
XTLB XTL Biopharmaceutica
2.5
EVAX Evaxion A/S
2.4
AARD Aardvark Therapeutic
6.1
LIPO Lipella Pharmaceutic
5.1

Valuation data pages: GLMD · TLSA · SLGL · EPRX · XTLB · EVAX · AARD · LIPO · ANTX · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like CANF on Quality?

Closest companies to CANF’s Quality of Company score of 2.5/10, across all industries.

Which Biotechnology Screens Does CANF Appear In?

Why Do CirclFi’s 0 Models Disagree on CANF?

What Are the Biggest Risks of Buying CANF Stock?

Weak Fundamentals

QOC 2.5/10 signals below-average quality.

Value Trap Warning

VT score 80/100 — apparent discount may mask decay.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CANF Data Page →

So Is Can-Fite BioPharma Ltd. (CANF) Worth Buying in 2026?

Can-Fite BioPharma Ltd. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. Can-Fite BioPharma Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About CANF Stock?

Should I buy CANF stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for CANF at $2.24. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Can-Fite BioPharma Ltd.?

Key risks include: an elevated Value Trap score of 80/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 2.5/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does CANF compare to its competitors?

Among Biotechnology peers, CANF holds a Quality Score of 2.5/10. Comparable companies include GLMD (QOC 2.5), TLSA (QOC 2.5), SLGL (QOC 2.5). The relative ranking helps investors identify whether CANF offers better fundamental quality than alternatives in the same sector.

Is CANF a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CANF's Quality Score of 2.5/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy CANF at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CANF.

View CANF Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →